A randomised trial of radiotherapy alone versus three cycles of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) chemotherapy plus radiotherapy versus six cycles of CHOP chemotherapy plus radiotherapy for early stage aggressive non-Hodgkin's lymphoma

Cancer Research UK (CRUK) (UK)0 个研究点目标入组 0 人开始时间: 2001年7月1日最近更新: 2019年12月10日

适应症

试验速览

暂无简介。

•1. Biopsy-proven non-Hodgkin's lymphoma of any of the following histologies: International Working Formulation groups F, G and H; Kiel Classification: centroblastic B-cell, pleomorphic medium and large T-cell, immunoblastic, large cell anaplastic and high grade unclassified; Revised European-American Classification of Lymphoid Neoplasms (REAL Classification): Diffuse large B-cell, anaplastic large cell, high-grade B-cell or Mucosa-associated lymphoid tissue (MALT) type, and peripheral T-cell
•2. WHO performance status 0, 1, 2
•3. Aged greater than 15 years
•4. No previous chemotherapy or radiotherapy 5. Normal lactic dehydrogenase (LDH)
•6. Stage I, IE, II, IIE, except bulky abdominal presentation
•7. No B symptoms
•8. No previous malignancy, except basal cell carcinoma of the skin or cervical carcinoma stage I
•9. No evidence of Human Immunodeficiency Virus (HIV) positively
•10. No contraindications to protocol treatments

•Patients with testicular, brain, gastrointestinal or skin primaries are excluded

发起方

Cancer Research UK (CRUK) (UK)